The Engine Behind ABBV Stock Has Real Parts

The drugmaker’s rapid stock gains have led to a premium valuation, forcing investors to question its capacity for future growth.

AbbVie (ABBV) stock has been on a tear, rewarding investors with a 40% return over the last twelve months and trading near its 52-week high. For anyone watching from the sidelines, this is the classic momentum question: a stock in a clear uptrend, powered by a real business, that forces a would-be buyer to ask if there is any value left, or if the ticket price already charges for the entire ride.

The run is real; the open question is whether there is anything left for a buyer at this price.

This engine is running on more than just hope.

AbbVie’s momentum is not speculative. The company’s operating margin over the last year was 33%, crushing the S&P 500 median of 18.4%. Its operating cash flow margin tells a similar story of efficiency, clocking in at 34% versus the market’s 22%. This isn’t a fluke; the company’s three-year average operating margin is a healthy 27%.

This financial power comes from a successful pivot in its immunology franchise. As the legacy drug HUMIRA faces biosimilar competition, new blockbusters have taken the lead. In its most recent quarter, sales of Skyrizi surged 29% to $4.5 billion, while Rinvoq sales grew 20% to $2.1 billion. The pipeline is also delivering, with recent data from a Crohn’s disease study showing a combination therapy with Skyrizi could double the rate of endoscopic remission compared to monotherapy.

A premium ticket is required for this ride.

The market sees this quality and is charging accordingly. AbbVie trades at a price-to-earnings multiple of 126.3, a stark premium to the S&P 500 median of 24.2. The price-to-sales multiple of 7.3 also stands well above the market median of 3.3. There is no discount here; buyers are paying for the performance they can see and the growth they anticipate. This kind of valuation isn’t unique to AbbVie; as another analysis notes, LLY has momentum, and the question is the price for that stock, too.

The honest catch for any buyer at these levels is the sheer intensity of competition. The immunology and oncology spaces are two of the most innovative and crowded fields in medicine. While AbbVie’s current products are leading, the pace of development across the industry is relentless. A competitor’s breakthrough or a clinical setback for a key pipeline asset could challenge the growth narrative that supports today’s premium valuation. For investors who prefer to bet on the entire theme rather than a single name, a healthcare ETF like XLV offers broader exposure.

The guidance for earnings per share is the number to watch.

Ultimately, the debate comes down to execution. For 2026, management is guiding for adjusted earnings per share in a range of 13.90 to 14.10. Notably, this represents a lowered forecast from a prior guide of 14.20. This revision provides the sharpest, most current test for investors. Watching whether AbbVie can meet and exceed the high end of this new range will be the clearest signal of whether the business engine is still pulling hard enough to justify its premium price.

If momentum backed by real numbers is your hunting ground, our Guidance Momentum screen tracks every S&P 500 name where a rising forecast is meeting real price strength.

Momentum Is A Better Servant Than Master

Buying strength works until the one quarter it does not, and the investors who get hurt worst are the ones who let a single winner become their whole portfolio.

The Trefis High Quality (HQ) Portfolio keeps the discipline for you: about 30 quality names across industries, selected on the fundamentals that power durable runs and re-balanced by rules rather than excitement. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Chase the runs you believe in, on top of a core that does not need any single one.